Andrew Paul Mazar - Feb 2, 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Scientific Officer, Director
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Feb 2, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 06:38 PM
Previous filing
Jan 4, 2022
Next filing
Apr 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +88.9K $0.00 88.9K Feb 2, 2022 Common Stock 88.9K $2.80 Direct F1
transaction MNPR Restricted Stock Units Award $0 +67.3K +290.54% $0.00 90.4K Feb 2, 2022 Common Stock 67.3K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
F2 RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)